Fractyl Health (GUTS) - Oversold Biomedical Optionality; A Long Trade into 2026 Readouts
Fractyl Health's share price has been crushed to penny-stock territory despite multiple positive clinical updates and tangible near-term clinical-program optionality. The company trades at a market cap of roughly $63M with enterprise value under $24M, negative free cash flow but identifiable upcoming program milestones. This trade idea takes a prag…